Zobrazeno 1 - 4
of 4
pro vyhledávání: '"59"'
Autor:
Gergana Zlateva, Andrew G. Bushmakin, Joseph C. Cappelleri, Robert M. Bennett, Alesia Sadosky
Publikováno v:
The Journal of Rheumatology. 36:1304-1311
Objective.The Fibromyalgia Impact Questionnaire (FIQ) is a disease-specific composite instrument that measures the effect of problems experienced by patients with fibromyalgia (FM). Utilization of the FIQ in measuring changes due to interventions in
Autor:
Ashima Makol, Steven R. Ytterberg, Caitrin M. Coffey, Michael D. Richter, Cynthia S. Crowson, Matthew J. Koster, Kenneth J. Warrington
Publikováno v:
The Journal of Rheumatology. 47:518-523
Objective.To characterize the indication, outcomes, and adverse effects of rituximab (RTX) treatment in a large single-center cohort of patients with systemic rheumatoid vasculitis (RV).Methods.We retrospectively reviewed the medical charts of 17 pat
Autor:
Joegi Thomas, Frances Elender, Karl Gaffney, Alex J. MacGregor, Helen Doll, Max Yates, Louise Hamilton, Loretta Dean
Publikováno v:
The Journal of Rheumatology. 42:1177-1185
Objective.To investigate, in a pilot randomized controlled trial, whether etanercept (ETN) 25 mg once weekly is effective at maintaining a clinical response in patients with ankylosing spondylitis (AS) who have responded to the standard 50 mg dose.Me
Autor:
Takao Koike, Naoki Ishiguro, Michio Suzukawa, Kazuhiko Inoue, Hisashi Yamanaka, Junnosuke Ryu, Koichi Fujii, Masayoshi Harigai, Shigeko Inokuma, Yoshiya Tanaka, Tsutomu Takeuchi, Bruce Freundlich
Publikováno v:
The Journal of Rheumatology. 36:898-906
Objective.Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN.Methods.Registrat